Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (4): 465-468.
DOI: 10.19803/j.1672-8629.20220643

Previous Articles     Next Articles

One case of tacrolimus-caused reversible posterior leukoencephalopathy syndrome after renal transplantation in children

ZHANG Zhiqi1,2, GUO Mingxing1△, XU Ye1,2, ZHANG Jian3, LIN Jun3#, CUI Xiangli1,*   

  1. 1Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;
    2Department of Pharmacy, Capital Medical University, Beijing 100069, China;
    3Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
  • Received:2022-11-04 Online:2023-04-15 Published:2023-04-20

Abstract: Objective To find out more about the reversible posterior leukoencephalopathy syndrome (RPLS) after solid organ transplantation (SOT) in children and to explore the methods of treatment. Methods The clinical data of a child with RPLS caused by tacrolimus after renal transplantation was analyzed. The clinical characteristics, treatment plans and outcomes of RPLS were reviewed by consulting related case reports. Results RPLS was related to high concentrations of tacrolimus, mainly manifested as nervous system symptoms with or without hypertension. Anti-hypertension and antiepileptic therapies and adjustment of immunosuppressants were popularly used. Most of the children could recover within a few weeks, but a small number of children would subsequently suffer neurological disorders or even die. Conclusion Blood concentrations of immunosuppressants in children after SOT have to be closely monitored while nervous system symptoms and blood pressure deserve attention. Early identification of RPLS and prompt treatment can improve the prognosis.

Key words: tacrolimus, reversible posterior leukoencephalopathy syndrome (RPLS), children, organ transplantation, neurological disorders, adverse drug reactiom

CLC Number: